GOOG - The virtual clinical trial service providers market
Roots Analysis has done a detailed study on Virtual Clinical Trial Service Providers Market, 2020-2050, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.
To order this 280+ page report, which features 180+ figures and 230+ tables, please visit this link
Key Market Insights
§ Currently, many companies claim to have advanced technology platforms, which enable them to decentralize the clinical research process, thereby, optimizing associated costs and the total time spent on conducting trials
§ The virtual clinical trials landscape is presently dominated by the presence of small-sized companies; majority of the players are headquartered in North America
§ Considering the cost and time-related benefits of using modern technology solutions in clinical research, several investors have opted to fund the initiatives of companies engaged in the development of such solutions
§ Case Study: Pharmaceutical players have already conducted a number of virtual clinical studies, mostly upon encountering constraints with the conventional approach and developing the means to overcome them
§ The annual number of virtual trials, across different therapeutic areas, is on the rise; leveraging telehealth platforms and remote monitoring systems, both small and established companies are using this format
§ The rising interest of stakeholders in decentralized clinical trials is evident in the growing partnership activity; companies inked deals based on a variety of collaboration models and applications, worldwide
§ Owing to the tremendous rise in cost and complexity of conventional clinical research, the market opportunity for virtual clinical trials is poised to grow at a CAGR of 14% till 2050
§ The projected opportunity within the virtual clinical trials market is expected to be well distributed within different phases of development and end users, across the globe
For more information, please visit https://www.rootsanalysis.com/reports/virtual-clinical-trial-service-provides-market.html
Table of Contents
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Existing Constraints in Clinical Research
3.2.1. Increasing Complexity and Cost of Trials
3.2.2. Evolving Regulatory Standards
3.2.3. Patient Recruitment and Retention Challenges
3.2.4. Data Handling-related Concerns
3.3. Virtual Clinical Trials
3.3.1. Key Aspects of Virtual Clinical Trials
3.3.1.1. Study Design
3.3.1.2. Patient Recruitment and Retention
3.3.1.3. Remote Monitoring
3.4.1.4. Data Collection and Analysis
3.3.2. Advantages and Disadvantages of Virtual Clinical Trials
3.4. Emerging Trends in Clinical Drug Development
3.4.1. Innovative Trial Designs
3.4.2. Real-world Evidence
3.4.3. Patient Centricity
3.4.4. Big Data Analytics
3.4.5. Blockchain Technology
3.5. Future Perspectives
4. VIRTUAL CLINICAL TRIAL SERVICE PROVIDERS: CURRENT MARKET LANDSCAPE
.1. Chapter Overview
4.2. Virtual Clinical Trial Service Providers: Overall Market Overview
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Geography
4.2.4. Analysis by Type of Service Offered
5. COMPANY PROFILES
5.1. Chapter Overview
5.2. Cambridge Cognition
5.2.1. Company Overview
5.2.2. Technology Overview
5.2.3. Recent Developments and Future Outlook
5.3. Center Point Clinical Services
5.3.1. Company Overview
5.3.2. Technology Overview
.3.3. Recent Developments and Future Outlook
5.4. eClinicalHealth
5.4.1. Company Overview
5.4.2. Technology Overview
5.4.3. Recent Developments and Future Outlook
5.5. IQVIA
5.5.1. Company Overview
5.5.2. Technology Overview
5.5.3. Recent Developments and Future Outlook
5.6. Mytrus (Medidata Solutions)
5.6.1. Company Overview
5.6.2. Technology Overview
5.6.3. Recent Developments and Future Outlook
5.7. PanAmerican Clinical Research
5.7.1. Company Overview
5.7.2. Technology Overview
5.7.3. Recent Developments and Future Outlook
5.8. Science 37
5.8.1. Company Overview
5.8.2. Technology Overview
5.8.3. Recent Developments and Future Outlook
5.9. VirTrial
5.9.1. Company Overview
5.9.2. Technology Overview
5.9.3. Recent Developments and Future Outlook
6. CASE STUDY: VIRTUAL CLINICAL TRIAL-RELATED INITIATIVES OF BIG PHARMA PLAYERS
6.1. Chapter Overview
6.2. Virtual Clinical Trial-Related Initiatives of Big Pharma Players
6.2.1. Pfizer
6.2.1.1. Initial Approach and Key Learnings
6.2.1.2. Future Perspective
6.2.2. Johnson & Johnson
6.2.2.1. Initial Approach and Key Learnings
6.2.2.2. Future Perspective
6.2.3. Sanofi
6.2.3.1. Initial Approach and Key Learnings
6.2.3.2. Future Perspective
6.2.4. Novartis
6.2.4.1. Initial Approach and Key Learnings
6.2.4.2. Future Perspective
6.2.5. GlaxoSmithKline
6.2.5.1. Initial Approach and Key Learnings
6.2.5.2. Future Perspective
6.2.6. Amgen
6.2.6.1. Initial Approach and Key Learnings
6.2.6.2. Future Perspective
6.2.7. AstraZeneca
6.2.7.1. Initial Approach and Key Learnings
6.2.7.2. Future Perspective
7. CASE STUDY: TRADITIONAL VERSUS VIRTUAL CRO
7.1. Chapter Overview
7.2. Comparison between Traditional and Virtual CROs
7.3. Key Attributes of a Virtual CRO
7.4. The Virtual Operating Model
7.5. Concluding Remarks
8. FUNDING AND INVESTMENT ANALYSIS
8.1. Chapter Overview
8.2. Types of Funding
8.3. Virtual Clinical Trial Service Providers: Funding and Investment Analysis
8.3.1. Analysis by Year of Investment
8.3.2. Analysis by Amount Invested
8.3.3. Analysis by Type of Funding
8.3.4. Most Active Players
8.3.5. Most Active Investors
8.4. Concluding Remarks
9. PARTNERSHIPS & COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Virtual Clinical Trial Service Providers: Partnership and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Focus Area Mentioned in Agreement
9.3.4. Analysis by Target Therapeutic Area Mentioned in Agreement
9.3.5. Analysis by Year of Partnership and Type of Partner
9.3.6. Most Active Players: Analysis by Number of Partnerships
9.3.7. Geographical Analysis
9.3.9. Intercontinental and Intracontinental Agreements
10. COVID-19 IMPACT
10.1. Chapter Overview
10.2. Impact of COVID-19 on Clinical Trials
10.3. Impact on Future Opportunity for Virtual Clinical Trials Service Providers
11. CLINICAL TRIAL ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Virtual Clinical Trials: Clinical Trial Analysis
11.3.1. Analysis by Trial Registration Year
11.3.2. Analysis by Trial Phase
11.3.3. Analysis by Trial Status
11.3.4. Analysis by Trial Design
11.3.5. Analysis by Type of Sponsor
11.3.6. Analysis by Target Therapeutic Area
11.3.7. Geographical Analysis by Number of Registered Trials
11.3.8. Geographical Analysis by Number of Patients Enrolled
12. MARKET OPPORTUNITY ASSESSMENT
12.1. Chapter Overview
12.2. Key Assumptions and Forecast Methodology
12.3. Virtual Clinical Trial Service Providers: Overall Market Opportunity, 2020-2050
12.3.1. Virtual Clinical Trial Service Providers Market Opportunity, 2020-2050: Distribution by Therapeutic Area
12.3.2. Virtual Clinical Trials Service Providers Market Opportunity, 2020-2050: Distribution by End-user
12.3.3. Virtual Clinical Trials Service Providers Market Opportunity, 2020-2050: Distribution by Trial Phase
12.3.4. Virtual Clinical Trials Service Providers Market Opportunity, 2020-2050: Distribution by Geography
12.4. Virtual Clinical Trial Services Market in North America, 2020-2050
12.4.1. Virtual Clinical Trial Services Market in North America: Distribution by Therapeutic Area, 2020-2050
12.4.1.1. Virtual Clinical Trial Services Market for Cardiovascular Disorders in North America, 2020-2050
12.4.1.1.1. Virtual Clinical Trial Services Market for Cardiovascular Disorders in North America, 2020-2050: Share of Phase I Studies
12.4.1.1.2. Virtual Clinical Trial Services Market for Cardiovascular Disorders in North America, 2020-2050: Share of Phase II Studies
12.4.1.1.3. Virtual Clinical Trial Services Market for Cardiovascular Disorders in North America, 2020-2050: Share of Phase III Studies
12.4.1.1.4. Virtual Clinical Trial Services Market for Cardiovascular Disorders in North America, 2020-2050: Share of Phase IV Studies
12.4.2.1. Virtual Clinical Trial Services Market for Infectious Disorders in North America, 2020-2050
12.4.2.1.1. Virtual Clinical Trial Services Market for Infectious Disorders in North America, 2020-2050: Share of Phase I Studies
12.4.2.1.2. Virtual Clinical Trial Services Market for Infectious Disorders in North America, 2020-2050: Share of Phase II Studies
12.4.2.1.3. Virtual Clinical Trial Services Market for Infectious Disorders in North America, 2020-2050: Share of Phase III Studies
12.4.2.1.4. Virtual Clinical Trial Services Market for Infectious Disorders in North America, 2020-2050: Share of Phase IV Studies
12.4.3.1. Virtual Clinical Trial Services Market for Metabolic Disorders in North America, 2020-2050
12.4.3.1.1. Virtual Clinical Trial Services Market for Metabolic Disorders in North America, 2020-2050: Share of Phase I Studies
12.4.3.1.2. Virtual Clinical Trial Services Market for Metabolic Disorders in North America, 2020-2050: Share of Phase II Studies
12.4.3.1.3. Virtual Clinical Trial Services Market for Metabolic Disorders in North America, 2020-2050: Share of Phase III Studies
12.4.3.1.4. Virtual Clinical Trial Services Market for Metabolic Disorders in North America, 2020-2050: Share of Phase IV Studies
12.4.4.1. Virtual Clinical Trial Services Market for Neurological Disorders in North America, 2020-2050
12.4.4.1.1. Virtual Clinical Trial Services Market for Neurological Disorders in North America, 2020-2050: Share of Phase I Studies
12.4.4.1.2. Virtual Clinical Trial Services Market for Neurological Disorders in North America, 2020-2050: Share of Phase II Studies
12.4.4.1.3. Virtual Clinical Trial Services Market for Neurological Disorders in North America, 2020-2050: Share of Phase III Studies
12.4.4.1.4. Virtual Clinical Trial Services Market for Neurological Disorders in North America, 2020-2050: Share of Phase IV Studies
12.4.5.1. Virtual Clinical Trial Services Market for Oncological Disorders in North America, 2020-2050
12.4.5.1.1. Virtual Clinical Trial Services Market for Oncological Disorders in North America, 2020-2050: Share of Phase I Studies
12.4.5.1.2. Virtual Clinical Trial Services Market for Oncological Disorders in North America, 2020-2050: Share of Phase II Studies
12.4.5.1.3. Virtual Clinical Trial Services Market for Oncological Disorders in North America, 2020-2050: Share of Phase III Studies
12.4.5.1.4. Virtual Clinical Trial Services Market for Oncological Disorders in North America, 2020-2050: Share of Phase IV Studies
12.4.6.1. Virtual Clinical Trial Services Market for Respiratory Disorders in North America, 2020-2050
12.4.6.1.1. Virtual Clinical Trial Services Market Opportunity for Respiratory Disorders in North America, 2020-2050: Share of Phase I Studies
12.4.6.1.2. Virtual Clinical Trial Services Market Opportunity for Respiratory Disorders in North America, 2020-2050: Share of Phase II Studies
12.4.6.1.3. Virtual Clinical Trial Services Market Opportunity for Respiratory Disorders in North America, 2020-2050: Share of Phase III Studies
12.4.6.1.4. Virtual Clinical Trial Services Market Opportunity for Respiratory Disorders in North America, 2020-2050: Share of Phase IV Studies
12.4.7.1. Virtual Clinical Trial Services Market for Other Therapeutic Areas in North America, 2020-2050
12.4.7.1.1. Virtual Clinical Trial Services Market Opportunity for Other Therapeutic Areas in North America, 2020-2050: Share of Phase I Studies
12.4.7.1.2. Virtual Clinical Trial Services Market Opportunity for Other Therapeutic Areas in North America, 2020-2050: Share of Phase II Studies
12.4.7.1.3. Virtual Clinical Trial Services Market Opportunity for Other Therapeutic Areas in North America, 2020-2050: Share of Phase III Studies
12.4.7.1.4. Virtual Clinical Trial Services Market Opportunity for Other Therapeutic Areas in North America, 2020-2050: Share of Phase IV Studies
12.5. Virtual Clinical Trial Services Market in Europe, 2020-2050
12.5.1. Virtual Clinical Trial Services Market in Europe: Distribution by Therapeutic Area, 2020-2050
12.5.1.1. Virtual Clinical Trial Services Market for Cardiovascular Disorders in Europe, 2020-2050
12.5.1.1.1. Virtual Clinical Trial Services Market for Cardiovascular Disorders in Europe, 2020-2050: Share of Phase I Studies
12.5.1.1.2. Virtual Clinical Trial Services Market for Cardiovascular Disorders in Europe, 2020-2050: Share of Phase II Studies
12.5.1.1.3. Virtual Clinical Trial Services Market for Cardiovascular Disorders in Europe, 2020-2050: Share of Phase III Studies
12.5.1.1.4. Virtual Clinical Trial Services Market for Cardiovascular Disorders in Europe, 2020-2050: Share of Phase IV Studies
12.5.2.1. Virtual Clinical Trial Services Market for Infectious Disorders in Europe, 2020-2050
12.5.2.1.1. Virtual Clinical Trial Services Market for Infectious Disorders in Europe, 2020-2050: Share of Phase I Studies
12.5.2.1.2. Virtual Clinical Trial Services Market for Infectious Disorders in Europe, 2020-2050: Share of Phase II Studies
12.5.2.1.3. Virtual Clinical Trial Services Market for Infectious Disorders in Europe, 2020-2050: Share of Phase III Studies
12.5.2.1.4. Virtual Clinical Trial Services Market for Infectious Disorders in Europe, 2020-2050: Share of Phase IV Studies
12.5.3.1. Virtual Clinical Trial Services Market for Metabolic Disorders in Europe, 2020-2050
12.5.3.1.1. Virtual Clinical Trial Services Market for Metabolic Disorders in Europe, 2020-2050: Share of Phase I Studies
12.5.3.1.2. Virtual Clinical Trial Services Market for Metabolic Disorders in Europe, 2020-2050: Share of Phase II Studies
12.5.3.1.3. Virtual Clinical Trial Services Market for Metabolic Disorders in Europe, 2020-2050: Share of Phase III Studies
12.5.3.1.4. Virtual Clinical Trial Services Market for Metabolic Disorders in Europe, 2020-2050: Share of Phase IV Studies
12.5.4.1. Virtual Clinical Trial Services Market for Neurological Disorders in Europe, 2020-2050
12.5.4.1.1. Virtual Clinical Trial Services Market for Neurological Disorders in Europe, 2020-2050: Share of Phase I Studies
12.5.4.1.2. Virtual Clinical Trial Services Market for Neurological Disorders in Europe, 2020-2050: Share of Phase II Studies
12.5.4.1.3. Virtual Clinical Trial Services Market for Neurological Disorders in Europe, 2020-2050: Share of Phase III Studies
12.5.4.1.4. Virtual Clinical Trial Services Market for Neurological Disorders in Europe, 2020-2050: Share of Phase IV Studies
12.5.5.1. Virtual Clinical Trial Services Market for Oncological Disorders in Europe, 2020-2050
12.5.5.1.1. Virtual Clinical Trial Services Market for Oncological Disorders in Europe, 2020-2050: Share of Phase I Studies
12.5.5.1.2. Virtual Clinical Trial Services Market for Oncological Disorders in Europe, 2020-2050: Share of Phase II Studies
12.5.5.1.3. Virtual Clinical Trial Services Market for Oncological Disorders in Europe, 2020-2050: Share of Phase III Studies
12.5.5.1.4. Virtual Clinical Trial Services Market for Oncological Disorders in Europe, 2020-2050: Share of Phase IV Studies
12.5.6.1. Virtual Clinical Trial Services Market for Respiratory Disorders in Europe, 2020-2050
12.5.6.1.1. Virtual Clinical Trial Services Market for Respiratory Disorders in Europe, 2020-2050: Share of Phase I Studies
12.5.6.1.2. Virtual Clinical Trial Services Market for Respiratory Disorders in Europe, 2020-2050: Share of Phase II Studies
12.5.6.1.3. Virtual Clinical Trial Services Market for Respiratory Disorders in Europe, 2020-2050: Share of Phase III Studies
12.5.6.1.4. Virtual Clinical Trial Services Market for Respiratory Disorders in Europe, 2020-2050: Share of Phase IV Studies
12.5.7.1. Virtual Clinical Trial Services Market for Other Therapeutic Areas in Europe, 2020-2050
12.5.7.1.1. Virtual Clinical Trial Services Market for Other Therapeutic Areas in Europe, 2020-2050: Share of Phase I Studies
12.5.7.1.2. Virtual Clinical Trial Services Market for Other Therapeutic Areas in Europe, 2020-2050: Share of Phase II Studies
12.5.7.1.3. Virtual Clinical Trial Services Market for Other Therapeutic Areas in Europe, 2020-2050: Share of Phase III Studies
12.5.7.1.4. Virtual Clinical Trial Services Market for Other Therapeutic Areas in Europe, 2020-2050: Share of Phase IV Studies
12.6. Virtual Clinical Trial Services Market in Asia-Pacific, 2020-2050
12.6.1. Virtual Clinical Trial Services Market in Asia-Pacific: Distribution by Therapeutic Area, 2020-2050
12.6.1.1. Virtual Clinical Trial Services Market for Cardiovascular Disorders in Asia-Pacific, 2020-2050
12.6.1.1.1. Virtual Clinical Trial Services Market for Cardiovascular Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies
12.6.1.1.2. Virtual Clinical Trial Services Market for Cardiovascular Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies
12.6.1.1.3. Virtual Clinical Trial Services Market for Cardiovascular Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies
12.6.1.1.4. Virtual Clinical Trial Services Market for Cardiovascular Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies
12.6.2.1. Virtual Clinical Trial Services Market for Infectious Disorders in Asia-Pacific, 2020-2050
12.6.2.1.1. Virtual Clinical Trial Services Market for Infectious Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies
12.6.2.1.2. Virtual Clinical Trial Services Market for Infectious Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies
12.6.2.1.3. Virtual Clinical Trial Services Market for Infectious Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies
12.6.2.1.4. Virtual Clinical Trial Services Market for Infectious Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies
12.6.3.1. Virtual Clinical Trial Services Market for Metabolic Disorders in Asia-Pacific, 2020-2050
12.6.3.1.1. Virtual Clinical Trial Services Market for Metabolic Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies
12.6.3.1.2. Virtual Clinical Trial Services Market for Metabolic Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies
12.6.3.1.3. Virtual Clinical Trial Services Market for Metabolic Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies
12.6.3.1.4. Virtual Clinical Trial Services Market for Metabolic Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies
12.6.4.1. Virtual Clinical Trial Services Market for Neurological Disorders in Asia-Pacific, 2020-2050
12.6.4.1.1. Virtual Clinical Trial Services Market for Neurological Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies
12.6.4.1.2. Virtual Clinical Trial Services Market for Neurological Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies
12.6.4.1.3. Virtual Clinical Trial Services Market for Neurological Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies
12.6.4.1.4. Virtual Clinical Trial Services Market for Neurological Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies
12.6.5.1. Virtual Clinical Trial Services Market for Oncological Disorders in Asia-Pacific, 2020-2050
12.6.5.1.1. Virtual Clinical Trial Services Market for Oncological Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies
12.6.5.1.2. Virtual Clinical Trial Services Market for Oncological Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies
12.6.5.1.3. Virtual Clinical Trial Services Market for Oncological Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies
12.6.5.1.4. Virtual Clinical Trial Services Market for Oncological Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies
12.6.6.1. Virtual Clinical Trial Services Market for Respiratory Disorders in Asia-Pacific, 2020-2050
12.6.6.1.1. Virtual Clinical Trial Services Market for Respiratory Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies
12.6.6.1.2. Virtual Clinical Trial Services Market for Respiratory Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies
12.6.6.1.3. Virtual Clinical Trial Services Market for Respiratory Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies
12.6.6.1.4. Virtual Clinical Trial Services Market for Respiratory Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies
12.6.7.1. Virtual Clinical Trial Services Market for Other Therapeutic Areas in Asia-Pacific, 2020-2050
12.6.7.1.1. Virtual Clinical Trial Services Market for Other Therapeutic Areas in Asia-Pacific, 2020-2050: Share of Phase I Studies
12.6.7.1.2. Virtual Clinical Trial Services Market for Other Therapeutic Areas in Asia-Pacific, 2020-2050: Share of Phase II Studies
12.6.7.1.3. Virtual Clinical Trial Services Market for Other Therapeutic Areas in Asia-Pacific, 2020-2050: Share of Phase III Studies
12.6.7.1.4. Virtual Clinical Trial Services Market for Other Therapeutic Areas in Asia-Pacific, 2020-2050: Share of Phase IV Studies
12.7. Virtual Clinical Trial Services Market in Rest of the World, 2020-2050
12.7.1. Virtual Clinical Trial Services Market in Rest of the World: Distribution by Therapeutic Area, 2020-2050
12.7.1.1. Virtual Clinical Trial Services Market for Cardiovascular Disorders in Rest of the World, 2020-2050
12.7.1.1.1. Virtual Clinical Trial Services Market for Cardiovascular Disorders in Rest of the World, 2020-2050: Share of Phase I Studies
12.7.1.1.2. Virtual Clinical Trial Services Market for Cardiovascular Disorders in Rest of the World, 2020-2050: Share of Phase II Studies
12.7.1.1.3. Virtual Clinical Trial Services Market for Cardiovascular Disorders in Rest of the World, 2020-2050: Share of Phase III Studies
12.7.1.1.4. Virtual Clinical Trial Services Market for Cardiovascular Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies
12.7.2.1. Virtual Clinical Trial Services Market for Infectious Disorders in Rest of the World, 2020-2050
12.7.2.1.1. Virtual Clinical Trial Services Market for Infectious Disorders in Rest of the World, 2020-2050: Share of Phase I Studies
12.7.2.1.2. Virtual Clinical Trial Services Market for Infectious Disorders in Rest of the World, 2020-2050: Share of Phase II Studies
12.7.2.1.3. Virtual Clinical Trial Services Market for Infectious Disorders in Rest of the World, 2020-2050: Share of Phase III Studies
12.7.2.1.4. Virtual Clinical Trial Services Market for Infectious Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies
12.7.3.1. Virtual Clinical Trial Services Market for Metabolic Disorders in Rest of the World, 2020-2050
12.7.3.1.1. Virtual Clinical Trial Services Market for Metabolic Disorders in Rest of the World, 2020-2050: Share of Phase I Studies
12.7.3.1.2. Virtual Clinical Trial Services Market for Metabolic Disorders in Rest of the World, 2020-2050: Share of Phase II Studies
12.7.3.1.3. Virtual Clinical Trial Services Market for Metabolic Disorders in Rest of the World, 2020-2050: Share of Phase III Studies
12.7.3.1.4. Virtual Clinical Trial Services Market for Metabolic Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies
12.7.4.1. Virtual Clinical Trial Services Market for Neurological Disorders in Rest of the World, 2020-2050
12.7.4.1.1. Virtual Clinical Trial Services Market for Neurological Disorders in Rest of the World, 2020-2050: Share of Phase I Studies
12.7.4.1.2. Virtual Clinical Trial Services Market for Neurological Disorders in Rest of the World, 2020-2050: Share of Phase II Studies
12.7.4.1.3. Virtual Clinical Trial Services Market for Neurological Disorders in Rest of the World, 2020-2050: Share of Phase III Studies
12.7.4.1.4. Virtual Clinical Trial Services Market for Neurological Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies
12.7.5.1. Virtual Clinical Trial Services Market for Oncological Disorders in Rest of the World, 2020-2050
12.7.5.1.1. Virtual Clinical Trial Services Market for Oncological Disorders in Rest of the World, 2020-2050: Share of Phase I Studies
12.7.5.1.2. Virtual Clinical Trial Services Market for Oncological Disorders in Rest of the World, 2020-2050: Share of Phase II Studies
12.7.5.1.3. Virtual Clinical Trial Services Market for Oncological Disorders in Rest of the World, 2020-2050: Share of Phase III Studies
12.7.5.1.4. Virtual Clinical Trial Services Market for Oncological Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies
12.7.6.1. Virtual Clinical Trial Services Market for Respiratory Disorders in Rest of the World, 2020-2050
12.7.6.1.1. Virtual Clinical Trial Services Market for Respiratory Disorders in Rest of the World, 2020-2050: Share of Phase I Studies
12.7.6.1.2. Virtual Clinical Trial Services Market for Respiratory Disorders in Rest of the World, 2020-2050: Share of Phase II Studies
12.7.6.1.3. Virtual Clinical Trial Services Market for Respiratory Disorders in Rest of the World, 2020-2050: Share of Phase III Studies
12.7.6.1.4. Virtual Clinical Trial Services Market for Respiratory Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies
12.7.7.1. Virtual Clinical Trial Services Market for Other Therapeutic Areas in Rest of the World, 2020-2050
12.7.7.1.1. Virtual Clinical Trial Services Market for Other Therapeutic Areas in Rest of the World, 2020-2050: Share of Phase I Studies
12.7.7.1.2. Virtual Clinical Trial Services Market for Other Therapeutic Areas in Rest of the World, 2020-2050: Share of Phase II Studies
12.7.7.1.3. Virtual Clinical Trial Services Market for Other Therapeutic Areas in Rest of the World, 2020-2050: Share of Phase III Studies
12.7.7.1.4. Virtual Clinical Trial Services Market for Other Therapeutic Areas in Rest of the World, 2020-2050: Share of Phase IV Studies
13. CONCLUSION
14. INTERVIEW TRANSCRIPTS
14.1. Chapter Overview
14.2. ConsilX
14.2.1. Interview Transcript: Himanshu Verma, Founder and Chief Executive Officer, ConsilX & Rajesh Jain, Co-Founder, ConsilX
14.3. EmpiraMed
14.3.1. Interview Transcript: Greg Erman, President and Chief Executive Officer, EmpiraMed
14.4. Andaman7
14.4.1. Interview Transcript: Phillipe Lemmens, Chief Operating Officer, Andaman7
14.5. uMotif
14.5.1. Interview Transcript: Jonathan Moshinsky, Head of Market Strategy, uMotif
15. APPENDIX 1: TABULATED DATA
16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415